| Jessika Jean Jamgochian, | |
|
333 Pine Ridge Blvd, Wausau, WI 54401-4187 | |
| (715) 847-2021 | |
| Not Available |
| Full Name | Jessika Jean Jamgochian |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 333 Pine Ridge Blvd, Wausau, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134607781 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 8472-33 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aspirus Wausau Hospital | Wausau, WI | Hospital |
| Ascension St Marys Hospital | Rhinelander, WI | Hospital |
| Aspirus Medford Hospital & Clinics, Inc | Medford, WI | Hospital |
| Aspirus Iron River Hospital & Clinics, Inc | Iron river, MI | Hospital |
| Aspirus Ironwood Hospital | Ironwood, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aspirus Medical Group Inc | 1052223625 | 212 |
News Archive
BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.
Watson Pharmaceuticals, Inc. today announced that the U.S. pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.
Inpatient hospital treatment accounts for the largest proportion of health care spending in the U.S., with the use of diagnostic imaging services such as MRIs, frequently implicated as the probable cause. A new analysis finds that the biggest expense may not be imaging technology but from supplies including medical devices, such as stents and artificial joints.
New research, published in The Lancet Oncology, has found that combining human papillomavirus (HPV) testing with routine liquid-based cytology (LBC) screening does not increase the detection of cervical cancer compared with LBC screening alone. The trial funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme aimed to determine whether testing for HPV in the cervix might increase the effectiveness of the cervical screening programme.
› Verified 9 days ago
| Entity Name | Aspirus Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669595294 PECOS PAC ID: 1052223625 Enrollment ID: O20031103000267 |
News Archive
BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.
Watson Pharmaceuticals, Inc. today announced that the U.S. pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.
Inpatient hospital treatment accounts for the largest proportion of health care spending in the U.S., with the use of diagnostic imaging services such as MRIs, frequently implicated as the probable cause. A new analysis finds that the biggest expense may not be imaging technology but from supplies including medical devices, such as stents and artificial joints.
New research, published in The Lancet Oncology, has found that combining human papillomavirus (HPV) testing with routine liquid-based cytology (LBC) screening does not increase the detection of cervical cancer compared with LBC screening alone. The trial funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme aimed to determine whether testing for HPV in the cervix might increase the effectiveness of the cervical screening programme.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessika Jean Jamgochian, 333 Pine Ridge Blvd, Wausau, WI 54401-4187 Ph: (715) 847-2021 | Jessika Jean Jamgochian, 333 Pine Ridge Blvd, Wausau, WI 54401-4187 Ph: (715) 847-2021 |
News Archive
BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.
Watson Pharmaceuticals, Inc. today announced that the U.S. pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.
Inpatient hospital treatment accounts for the largest proportion of health care spending in the U.S., with the use of diagnostic imaging services such as MRIs, frequently implicated as the probable cause. A new analysis finds that the biggest expense may not be imaging technology but from supplies including medical devices, such as stents and artificial joints.
New research, published in The Lancet Oncology, has found that combining human papillomavirus (HPV) testing with routine liquid-based cytology (LBC) screening does not increase the detection of cervical cancer compared with LBC screening alone. The trial funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme aimed to determine whether testing for HPV in the cervix might increase the effectiveness of the cervical screening programme.
› Verified 9 days ago
Ms. Jacquelyn Forbes Kearns, MS,ARNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2727 Plaza Dr, Wausau, WI 54401 Phone: 715-847-3000 | |
Alicia Schumacher, AANPCP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 520 N 32nd Ave, Wausau, WI 54401 Phone: 715-847-2424 | |
Kyla P Teresinski, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 510 N 17th Ave Ste C, Wausau, WI 54401 Phone: 715-849-5333 Fax: 715-849-4083 | |
Marietta S Kern, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 218 N 28th Ave, Wausau, WI 54401 Phone: 715-847-2866 | |
Bradley A Mueller, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 225000 Hummingbird Rd Ste 100, Wausau, WI 54401 Phone: 715-359-6442 Fax: 715-393-0390 | |
Gina E Ramthun, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1901 Westwood Center Blvd, Wausau, WI 54401 Phone: 715-355-9424 | |
Tiffany Pluger, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2400 Marshall St Ste A, Wausau, WI 54403 Phone: 715-848-4356 Fax: 715-845-5398 |